

Laforin (S-19): sc-70293

BACKGROUND

Laforin (Lafora PTPase) is a dual specificity protein phosphatase expressed in heart, skeletal muscle, kidney, pancreas and brain. It belongs to the protein-tyrosine phosphatase family and contains one CBM20 (carbohydrate binding type-20) domain and one tyrosine-protein phosphatase domain. Laforin may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules (polyglucosans). Laforin isoform 1 is primarily associated with polyribosomes at the endoplasmic reticulum, however, it is also found at the plasma membrane. Isoform 2 can be found in the nucleus. Defects in the EPM2A gene are a cause of progressive myoclonic epilepsy type 2 (EPM2), also known as Lafora disease. EPM2 is an autosomal recessive disease and a severe form of adolescent-onset progressive epilepsy.

REFERENCES

1. Ganesh, S., et al. 2000. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. *Hum. Mol. Genet.* 9: 2251-2261.
2. Ganesh, S., et al. 2001. Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene. *Mol. Cell. Probes* 15: 281-289.
3. Wang, J., et al. 2002. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. *J. Biol. Chem.* 277: 2377-2380.
4. Ganesh, S., et al. 2002. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. *Hum. Mol. Genet.* 11: 1263-1271.
5. Ganesh, S., et al. 2002. Alternative splicing modulates subcellular localization of Laforin. *Biochem. Biophys. Res. Commun.* 291: 1134-1137.
6. Ki, C.S., et al. 2003. Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy. *J. Hum. Genet.* 48: 51-54.

CHROMOSOMAL LOCATION

Genetic locus: EPM2A (human) mapping to 6q24.3; Epm2a (mouse) mapping to 10 A1.

SOURCE

Laforin (S-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of Laforin of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-70293 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

Laforin (S-19) is recommended for detection of Laforin of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Laforin (S-19) is also recommended for detection of Laforin in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for Laforin siRNA (h): sc-75405, Laforin siRNA (m): sc-75406, Laforin shRNA Plasmid (h): sc-75405-SH, Laforin shRNA Plasmid (m): sc-75406-SH, Laforin shRNA (h) Lentiviral Particles: sc-75405-V and Laforin shRNA (m) Lentiviral Particles: sc-75406-V.


Molecular Weight of Laforin: 38 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227, HeLa whole cell lysate: sc-2200 or Raji whole cell lysate: sc-364236.

DATA



Laforin (S-19): sc-70293. Western blot analysis of Laforin expression in Hep G2 (A), HeLa (B) and Raji (C) whole cell lysates.



Laforin (S-19): sc-70293. Immunoperoxidase staining of formalin fixed, paraffin-embedded human salivary gland tissue showing nuclear and cytoplasmic staining of glandular cells.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **Laforin (k2A3): sc-135810**, our highly recommended monoclonal alternative to Laforin (S-19).